Wall Street analysts expect that Esperion Therapeutics Inc (NASDAQ:ESPR) will report ($1.77) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($1.53) and the lowest is ($1.93). Esperion Therapeutics reported earnings per share of ($1.92) in the same quarter last year, which suggests a positive year-over-year growth rate of 7.8%. The company is scheduled to announce its next earnings results on Tuesday, August 14th.
On average, analysts expect that Esperion Therapeutics will report full year earnings of ($6.31) per share for the current fiscal year, with EPS estimates ranging from ($6.55) to ($6.05). For the next year, analysts forecast that the firm will report earnings of ($5.95) per share, with EPS estimates ranging from ($6.74) to ($5.47). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.56) by ($0.17). During the same period in the previous year, the firm earned ($1.80) earnings per share.
A number of brokerages have weighed in on ESPR. JMP Securities lifted their price objective on Esperion Therapeutics from $60.00 to $153.00 and gave the company an “outperform” rating in a report on Thursday, March 8th. Deutsche Bank lifted their price objective on Esperion Therapeutics to $100.00 and gave the company a “buy” rating in a report on Friday, March 9th. Northland Securities lifted their price objective on Esperion Therapeutics from $100.00 to $121.00 and gave the company a “buy” rating in a report on Thursday, April 19th. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 20th. Finally, Stifel Nicolaus set a $105.00 price objective on Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, March 7th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $89.08.
ESPR traded up $1.31 during trading on Friday, reaching $38.50. The company’s stock had a trading volume of 578,863 shares, compared to its average volume of 991,272. Esperion Therapeutics has a 52-week low of $33.06 and a 52-week high of $82.68. The firm has a market capitalization of $1.02 billion, a PE ratio of -5.52 and a beta of 2.37.
In related news, major shareholder Target N. V. Biotech purchased 60,000 shares of Esperion Therapeutics stock in a transaction dated Tuesday, June 5th. The stock was bought at an average cost of $38.47 per share, for a total transaction of $2,308,200.00. Following the transaction, the insider now owns 3,012,964 shares in the company, valued at $115,908,725.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of Esperion Therapeutics stock in a transaction dated Friday, May 18th. The shares were bought at an average price of $42.24 per share, with a total value of $2,112,000.00. Following the completion of the transaction, the insider now owns 2,872,964 shares in the company, valued at approximately $121,353,999.36. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 360,000 shares of company stock valued at $14,216,100. Insiders own 32.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP raised its position in shares of Esperion Therapeutics by 348.6% during the 1st quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,234 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in Esperion Therapeutics in the 1st quarter worth approximately $231,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Esperion Therapeutics in the 4th quarter worth approximately $222,000. Xact Kapitalforvaltning AB purchased a new stake in Esperion Therapeutics in the 1st quarter worth approximately $250,000. Finally, BB&T Securities LLC purchased a new stake in Esperion Therapeutics in the 4th quarter worth approximately $263,000. Institutional investors own 98.39% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.